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A b s t r a c t  
The aim of this study was to formulate KF fast disintegrating sublingual tablets (FDSLTs).  KF 
undergoes first pass metabolism in liver, which has oral bioavailability of only 50% of the 
administrated dose. Sublingual dosage form bypasses the metabolism of KF in liver and offers a fast 
relieve of asthma. To achieve this goal, superdisintegrants and diluents were evaluated for their 
effect on the disintegration behavior of KF tablets.   Full factorial design (24) was applied for a 
screening study in which four factors were used at two levels (low and high). The four factors, were 
the type of disintegrants either Ac-di-sol or Explotab, the concentration of each disintegrant (either 
3% or 5% w/w), the binder either Avicel PH101 or PEG6000 and finally the diluent was either spray 
dried lactose or granular mannitol. The weight variation, content uniformity, friability, hardness, 
disintegration time, and in-vitro dissolution of the prepared formulae were evaluated. Hydroxy 
propyle betacyclodextrin (2-HP-β -CD) was used for increasing the absorption of KF tablets formulae. 
Solid binary system of KF with betacyclodextrin (2HP--β -CD) was prepared in molar ratios of 1:1 of 
drug to cyclodextrin. The formula F9 containing Ac-di-sol(5%w/w) , Avicel PH101(10%w/w) and 
granular mannitol as diluent was selected as best formula that has the least disintegration time  of 20 
seconds and the highest cumulative dissolution percent of 80.28% after the first minute. The relative 
bioavailability of F9 both with and without the cyclodextrin was compared.  Zaditen® tablets were 
taken as reference standard.  The formula F9 showed mean peak plasma concentration Cmax of 
25.578±2.65ng/mL, the mean time of peak plasma concentration tmax of 1.167±0.258 h and the 
AUC (0-∞) of 319.894± 69.13ng.h/mL. However, FC9 that containing the drug in the form of a 
complex with 2HP-β  CD showed Cmax of 30.901±4.963ng/mL, tmax of 1.083±0.186h and AUC (0-∞) 
of 382.166±55.278ng.h/mL. The results indicate that KF/2-HP-β CD fast disintegrating sublingual 
tablets may serve as a successful strategy for enhancing the bioavailability of KF drug.  
Keywords: Sublingual tablets, Ketotifen Fumarate, 2-HP-β CD, Fast disintegration, Bioavailability. 
 
Introduction 
Ketotifen is a non-specific mast cell stabilizer, which can prevent 
the development of asthmatic conditions by H1-receptor 
antagonism, phosphodiestrase inhibition resulting in accumulation 
of cyclic adenosine mono-phosphate (c AMP) inside the cells, 
inhibition of the release of inflammatory mediators SRS (slow 
reacting substance of anaphylaxis) and inhibition of calcium flux in 
bronchial smooth muscle [2, 3].  Moreover, early treatment with 
ketotifen limits the need for other anti-asthmatic drugs including 
steroids [4].   
Various techniques can be used to formulate rapidly disintegrating 
or dissolving tablets of ketotofen fumerates [4]. Direct 
compression is the easiest way of manufacturing tablets. The  
 
 
 
 
 
 
 
biggest advantages are the low manufacturing cost, high 
mechanical property of the tablets and it is the ideal method for 
moisture and heat-labile medications [5].  Cyclodextrins and their 
derivatives have been frequently used to enhance the 
bioavailability by increasing the drug solubility, dissolution and/or 
permeability [6].  They also act as penetration enhancers by 
increasing the drug availability at the surface of biological barrier 
[7]. Cyclodextrins have also been beneficial in reducing the 
undesirable properties of drugs, like gastric irritation [8], masking 
unpleasant tastes or odors [9].  The purpose of this study was to 
engineer a fast disintegrating sublingual tablets that bypass the 
hepatic metabolism, improve the patient compliance which are 
able to enhance the permeability and bioavailability of selected 
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formulae through complexation with 2-HP-β -CD.  Evaluation of the 
complex as an absorption enhancer using six male volunteers and 
was carried out to compare the bioavailability of the prepared 
FDSLTs formula with the marked formula (Zaditen® tablets).  
Materials and Methods  
Materials: Ketotifen fumarate (generously gifted by Memphis 
Co., Egypt); 2-Hydroxy propyl- ß-cyclodextrin (chemical Co., 
Milwaukee, WI, USA).  Polyethylene glycols 6000 (Fluka AG 
Buchs SG, Switzerland); Avicel PH 101: microcrystalline cellulose, 
(FMC Corporation, Pennsylvania, USA); Aerosil 200: colloidal 
silicon dioxide (Degussa-Huls Ltd., Frankfurt, Germany); 
Explotab: sodium starch glycolate and Ac-di-sol: crosscarmellose 
sodium(FMC corporation, Philadelphia ,USA); magnesium 
stearate, (Prolabo, France); spray dried lactose and granular 
mannitol (spray-dried NF, Fast Flo; Foremost Farms, Baraboo, 
WI).  
Tablet preparations: 
Fast disintegrating sublingual tablets were prepared by direct 
compression technique.    A full factorial design (24) was applied 
for the screening study in which four factors were used at two 
levels. These factors were the type of superdisintegrants either 
Ac-di-sol or Explotab, the concentration of superdisintegrants 
either low (3%w/w) or high (5%w/w), the type of  binder either 
Avicel PH101 or PEG6000 at concentration of (10%w/w) and 
finally the type of  diluent  either  spray dried lactose or granular 
mannitol.  A combination of magnesium stearate (1% w/w), 
aspartam (1% w/w) as sweetening agent, mint flavor (0.5% w/w) 
and Aerosil 200 (2% w/w) which is used  as permeabilizing and 
antistatic glidant were all  combined for the preparation of FDSLTs 
as shown in the  table 1.  All the ingredients of the sublingual 
tablets of KF were weighed and mixed in a mortar  and pestle, 
then finally magnesium stearate (1mg) and Aerosil(2mg)   were  
added for   a good lubrication  characteristics. The blended 
material was slightly compressed on the flat–faced punch (7mm) 
using a single punch machine (Erweka type, GmbH, Germany).  
The total weight of the formula was maintained at 100mg. 
Evaluation of the prepared fast disintegrating 
sublingual tables 
All the prepared tablets of formulae from F1 to F16 were 
evaluated for their weight variations, friability, hardness, drug 
content, disintegration and dissolution rate and weight variation 
tests were evaluated using twenty tablets of each formula 
randomly, and individually weighed.  No more than two of  the 
individual tablets deviate from the average weight by more than 
5%, and none deviate by more than twice that percentage [10-12].  
Friability was tested using friabilator, Pharma test, (Erweka type, 
GmbH, Germany).  Carried out according to British 
pharmacopoeia (B.P.) [11] while hardness was investigated using 
Erweka hardness tester (M6d, Drish leuniger, Pharmaton). For the 
disintegration time test; the tablets were inserted in each of the six 
cells of the disintegrator, USP Disintegration tester apparatus 
(Hanson research,USA) ; In this experiment simulated saliva fluid 
(SSF) pH=6.75 kept at 37 ± 1°C  was carried out on the 
disintegration apparatus and the basket was raised and lowered 
at a constant frequency of 30±2 cycles/min. The test results were 
presented as the average of six determinations. For each formula 
the total time of disintegration was measured [13, 14]. The content 
of KF in different tablets was determined by accurately weighing 
ten tablets of each formula individually. Each tablet was crushed 
and dissolved in methanol (8 mL) that is  placed in a volumetric 
flask(10ml).  The solution was filtered, suitably diluted and the 
drug content was analyzed spectrophotometrically (Shimadzu, 
UV-1601) at 300nm. 
Enhancing the permeability of Selected Ketotifen 
Fumarate Fast Disintegrating Sublingual tablets via the 
complexation with 2-HP- β -CD: 
Only eight formulae out of the sixteen formulae (from F1 to F16),  
which pass the previous  quality control were chosen to  forms 
inclusion complex with   2-HP-β -CD in molar ratio ( 1:1) by 
precipitation method.  The clear solutions of HP-ß-CD in distilled 
water and KF in ethanol-water (80:20, v/v) solution were mixed at 
the molar ratios of (1:1). The obtained solution was dried under 
vacuum at room temperature using a rotary evaporator. The 
selected formulae were F1, F2, F3, F9, F11, F12, F13 and F16. 
Tablets were prepared as mentioned before  by replacing 
Ketotofen fumerate with  ketotifen fumarate/ 2-HP-β -CD  complex  
in a molar ratio  of 1:1. All  other additives were added  to have 
eight new formulae namely;  Fc1, Fc2, Fc3, Fc9, Fc11, Fc12, Fc13 
and Fc16 ( where c refers to complex formation of ketotifen 
fumarate and 2-HP-β -CD). The complex of KF and 2-HP-β -CD in 
(1:1) molar ratio was prepared by coprecipitation method and 
characterized  by differential scanning calorimetry (DSC)  and  X-
ray powder diffractometry (XRD) as  reported by our group [15] . 
Characterization of ketotifen fumarate/ 2-HP-β -CD fast 
disintegrating sublingual tablet 
The prepared KF/2-HP-β -CD fast disintegrating sublingual tablets 
namely; Fc1, Fc2, Fc3, Fc9, Fc11, Fc12, Fc13 and Fc16 were 
subjected to the following quality control tests:  Friability test, 
Hardness test, Disintegration time and Content uniformity as 
prescribed before. In addition, to determine the oral disintegration 
time and in- vitro dissolution studies for 5 minutes for choosing the 
best formula for bioequivalence study.  
In-vivo disintegration time 
The in vivo disintegration time of each of the prepared FDSLTs 
was evaluated in six human volunteers. All volunteers were asked 
to rinse their mouth with distilled water. Each of the six subjects 
was given a coded tablet. Tablets were placed under the tongue 
and immediately the time of the disintegration was recorded.  The 
subjects were asked to spit out the content of the oral cavity after 
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tablet disintegration and rinse their mouth with distilled water. The 
swallowing of saliva was prohibited during the test, and saliva was 
rinsed from the mouth after each measurement. The test results 
are presented as mean value ± SD. 
In-vivo absorption studies 
The studies were carried out to compare the pharmacokinetics of 
KF from a FDSLTs formula (F9 treatment A)  and formula  (Fc9 
treatment B)  in comparison to the conventional Zaditen® tablet 
(Novartispharma , Egypt) and labeled as  treatment C.   A single 
dose  of ketotifen, fumarate (1.38mg )  was given to the 
volunteers using  randomized, single dose, three-way crossover 
open-label study randomized crossover design (table 2). 
Six healthy man volunteers aged between 20 to 40 years (median 
weight: 75 kg and median height: 183 cm) were chosen. Health 
status of the volunteers was confirmed by complete medical 
history, physical examination and laboratory analysis for complete 
hematological and biochemical examination, all these were 
carried out at baseline.  None of the volunteers had any history of 
drug or alcohol abuse, nor did they have any acute or chronic 
gastrointestinal, cardiac, vascular, hepatic or renal disease.  The 
protocol of the study was conducted according to Helsinky 
agreement protocol and according to the requirements of the 
ethical committee of the faculty of Medicine , The University  of 
Beni Suef, Beni Suef, Egypt. 
 
The drug was administered orally after fasting overnight and 
washout period of 1 week. Venous blood samples (5 mL) were 
collected into heparinized tubes at the following time intervals: 0, 
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 h after administration of a 
treatment. Plasma was obtained by centrifugation at 2000 rpm for 
10 min and stored at -20ºC until the time of analysis. 
Chromatographic conditions 
A modified HPLC method of  [ for the determination of ketotifen 
fumarate in plasma was adopted [16].  The HPLC apparatus 
consisted of: Isocratic pump LC-10 AS and  a UV/VIS detector 
SPD-10A connected to a C-R6A Integrator (Shimadzu, Koyoto, 
Japan). The analytical column was Ponapak C18 HPLC column, 
4.6 × 250 I.D mm, particle size 125 ºA (Waters Associates, 
Ireland). The mobile phase composed of methanol: water in a 
ratio of 80:20 (V/V) containing triethaylamine (0.2%v/v), with a 
flow rate of 1 ml. min-1. The system was operated at ambient 
temperature and the detection wavelength was carried out at 296 
nm. 
Plasma analysis 
One mL of the plasma sample was mixed with acetonitrile (1 mL) 
and stock solution of the internal standard (1 mL). The mixture 
was vortexed for 1min and then centrifuged for 10 min at 3000 
rpm. The upper layer was separated and transferred to another 
tube then filtered through 0.45 μ m Millipore® filter for analysis with 
HPLC.  Twenty μ L of the samples were injected to the column for 
analysis. The recovery (10-600ng/mL) varied between 91.55 and 
100.86%.  
Pharmacokinetic analysis 
Pharmacokinetic characteristics from plasma data following 
administration of the two treatments were estimated for each 
subject using, WinNonlin® (version 1.5, Scientific consulting, Inc., 
Cary, NC, USA). Non-compartmental analysis was used.  Cmax 
(ng/mL) and tmax (h) were the observed maximal drug 
concentration and the time needed to reach this concentration 
respectively. The area under the curve, AUC(0-24) (ng.h/mL) was 
calculated using the trapezoidal rule from zero time to the last 
time of the blood sample. The area under the curve from zero to 
infinity, AUC(0-∞) (ng.h/mL), was calculated as AUC (0-∞) = AUC (0-
24) + Ct/k, where Ct is the last measured concentration at time t, 
and k is the terminal elimination rate constant estimated by log-
linear regression analysis on data visually assessed to be at 
terminal log-linear phase. Apparent terminal elimination half-life 
(t1/2) was calculated as t1/2 = 0.693/k. Mean residence time (MRT) 
was calculated from AUMC/AUC. The relative bioavailability was 
calculated as (AUC test / AUC standard) x100. 
 
Statistical analysis 
An analysis of variance (ANOVA) was performed for 
untransformed data for the pharmacokinetic parameters Cmax, 
tmax, AUC0–24, and t 1/2 using the software SPSS 11.0 (SPSS Inc., 
Chicago, USA) at p-value (p ≤ 0.05).  
Results and Discussion 
Evaluation of the fast disintegrating sublingual tablets 
Table 3, shows the data obtained from the evaluation of tablets.  
All the fast disintegrating sublingual KF formulae in the factorial 
design complied with the compendia standards for the weight 
variation and content uniformity tests (all tablet formulae were 
found to conform to pharmacopoeial limit 85% - 115%) of the label 
claim.  The prepared tablets showed a uniformity of diameter and 
thickness. 
 Tablet hardness 
All the tablets maintained hardness in the range of 4.14 to 7.62 
kilograms. The statistical analysis revealed that all factors; 
superdisintegrant type, superdisintegrant concentration, binder 
type, and diluent exhibited a significant effect on the hardness of 
the prepared formulae (p ≤ 0.05) as shown in figure 1.  
 Tablet Friability 
According to compendial standards of the British pharmacopoeia, 
the tablets comply with the friability test if the weight loss during 
the test was less than 1% of the given weight. The tablets should 
not break or show any capping or cracking during the test.  Table 
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3,  shows that the tablets formulated with the different excipients 
showed low percentage of  fines within the acceptable range 
except for only two formulae, namely F10 (containing 5% Ac-di-
sol  together with 10%Avical PH101 and lactose) and F14 
(containing 5% Explotab together with 10% Avical PH101 and 
lactose).   In addition, formula F4 and F15 had one broken 
tablet.Although many formulae had high friability values, yet they 
are still within the permissible limits. It is not surprising to find 
these percentage weight loss values owing to the nature of the 
rapidly disintegrating tablets which require certain packaging 
materials [17] .   
In-vitro disintegration test 
The shortest disintegration time were observed from F9, F10, 
F13, and F14 having average disintegration time of 24.13, 34.79, 
28.29 and 35.68 seconds, respectively. This might be due to the 
synergistic effect of both of Avicel PH101 and the higher 
concentration of the superdisintegrants either Ac -di-sol or 
Explotab in those formulae (AvicelPH10l works as a disintegrant 
in concentration of 5-15%).  ANOVA test at p ≤ 0.05  was carried 
out followed with Fischer's PLSD test (pair-wise least significant 
difference) to test the significance of the difference between the 
tested factors and their effects on tablet disintegration time at 95% 
confidence limits which, found that all factors under study, 
namely, superdisintegrant type, superdisintegrant concentration, 
binder types  and diluent types had significant effects on the 
disintegration time of the prepared FDSLTs (p<0.05) , the results 
were graphically illustrated in (figure 2).  
In-vitro dissolution studies: 
Ideally, physiological conditions at the site of administration 
should be taken into account when selecting the in-vitro 
dissolution/release test condition the saliva ordinary maintains the 
pH of the mouth between 5.6 and 7.6.  Therefore, in the 
dissolution studies, simulated saliva fluid (SSF) that has a pH of 
6.8±0.5 was adopted as a dissolution  medium [18].   All the 
examined formulae showed 100% drug dissolution after 5 minutes 
due to the water solubility of the drug. 
Enhancing the permeability of selected ketotifen 
fumarate fast disintegrating sublingual tablets through 
the complexation with 2-HP-β -CD 
The permeability of selected formula can be enhanced through 
complexation with 2-HP-β -CD.  Cyclodextrins and their derivatives 
have been frequently used to enhance the bioavailability by 
increasing the drug solubility, dissolution and/or permeability [6].  
They also act as penetration enhancers by increasing the drug 
availability at the surface of biological barrier [7].  The 
physicochemical characterization of KF/2-HP-β -CD  binary solid 
systems were proved by differential scanning calorimetry (DSC)  
and  X-ray powder diffractometry (XRD) [6] as illustrated in (figure 
3 and 4). 
Characterization of KF/ 2-HP-β -CD fast disintegrating 
sublingual tablets 
Concerning the content uniformity of the prepared formulae, it was 
found that the selected formulae were complying with the USP 
specification for content uniformity where the amount of the drug 
determined lied within the acceptable range  from 98.44% to 
102.57 % of the claimed dose.  Regarding hardness, friability and 
disintegration time, there was no significant difference before and 
after the complexation. All the prepared formulae containing drug 
complex showed acceptable hardness, friability and in-vitro 
disintegration times less than one minute were subjected to 
measurement of the  buccal disintegration time and in-vitro 
dissolution studies for 5 minutes for choosing the best formula.  
Buccal Disintegration Time 
The average buccal disintegration time arranged in the following 
order:  Fc9 > Fc13 > Fc11 > Fc2 > Fc16 >Fc3 > Fc1 > Fc12. 
The percent of ketotifen fumarate within five minutes 
The percentages of ketotifen fumarate dissolved after 1 minute 
can be arranged in the following order:  Fc9 > Fc13 > Fc1 > Fc2> 
Fc11 >Fc3 > Fc12 > Fc16. 
FC9 containing the complex system (KF: 2-HP-β -CD), Ac-di-sol 
(5%w/w), Avicel PH101(10%w/w) as a binder and  mannitol as 
diluent , showed the highest amount of drug dissolved after 1 
minute and minimum buccal disintegration time. Therefore, FC9 
was subjected to bioequivalence studies. 
In-vivo Study: 
Data from HPLC were presented as ratios of the peak area of the 
drug (ketotifen fumarate) to the peak area of the internal standard 
(Metrinidazole) for each sample. Concentrations of the samples 
withdrawn from volunteers were then determined by comparing 
the test samples. All the pharmacokinetic parameters were 
evaluated using WinNonLin® Professional.  The mean plasma 
concentration–time courses for KF following the administration of 
FDSLTs  F9 (contains KF without compelxation with 2HP-β CD); 
Fc9 and Zaditen® tablet in six healthy volunteers (figure 8).  The 
rate and extent of absorption of  KF  were found to be different 
following the three treatments, expressed with  higher Cmax by 
about 60% and 90% for both FDSLTs of F9 and Fc9 respectively,  
and earlier tmax (by 1 h) values for  both of  FDSLTs F9 and Fc9 
compared with Zaditen®. The mean Cmax estimated from F9 and 
Fc9 were 25.578±2.65 ng/mL and 30.901±4.963 ng/mL, 
respectively, while it was 16.0857±1.628, ng/mL for Zaditen® 
tablets the differences between the three treatments for Cmax was 
statistically significantly different (p < 0.05).  The mean AUC0–24 
estimate from FDSLTs was which reflects the total amount of drug 
absorbed over the 24 h time period, was found to be  161.237 
±16.78 ng h/mL, 210.102±36.99 ng h/mL and 246.192±32.33 ng 
h/mL  for Zaditen®  tablets,F9,Fc9 respectively, and  determined 
to be statistically significant different  (p < 0.05).   
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Moreover, it was worthy to note that the relative bioavailability for 
Fc9 of ketotifen fumarate fast disintegrating sublingual tablets was 
much higher than that of F9. The relative bioavailability of Fc9 
was 152.45% compared to 130.304% for F9 when Zaditen® 
tablets were taken as reference standard. 
The higher Cmax and faster tmax  observed after FDSLTs F9 and 
Fc9 than the commercially available conventional tablet 
(Zaditen®) may be attributed to the  rapid disintegration and 
dissolution of the drug in the saliva even with the absence of 
water.  Moreover in case of FDSLTS, the drug absorbed through 
the epithelium of sublingual membrane of the buccal mucosa and 
consequently  the bioavailability may increase [19].   Moreover, 
the  rapid and efficient absorption of KF from the buccal mucosa, 
pharynx and esophagus as the saliva passes down into the 
stomach (pregastric absorption)[20] resulting in a decreased pre-
systemic biotransformation.  The increased relative bioavailability 
of Fc9 compared F9 might be due to the effect of  2-HP-β CD 
incorporated product which have the ability to interact with 
macromolecules of sublingual membrane more efficiently causing 
marked improvement in the drug sublingual absorption [21, 22]. 
The ability of 2-HP-b CD to augment the extent and stability of 
supersaturated solutions of various poorly water soluble drug 
candidates with consequent improvement of their oral 
bioavailability has been assessed by Vandecruys et al [23].  An  
additional factor that could contribute to the improved of oral 
absorption and enhanced bioavailability of drugs by hydrophilic 
cyclodextrins is the increased permeation of drug molecules 
across the membrane lipid bilayers, as a result of their enhanced 
availability at the biological barrier and the alteration of the 
membrane fluidity [24-26].  
Conclusion 
The development of KF fast disintegrating sublingual tablets 
containing 2-HP-β CD as a complex with KF is a promising formula 
resulted in successful KF delivery to blood stream with 
significantly higher bioavailability when compared to the 
commercial product. The study suggests that   (Fc9) formula 
developed in this piece of work may be an alternative to 
conventional formulae of KF, such as oral tablets, that are 
reported to suffer from extensive hepatic metabolism or that are 
not convenient to the geriatric or pediatric patients who have 
swallowing difficulties. 
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Table 1: composition of ketotifen fumarate fast disintegrating sublingual tablets using factorial design.  
All formulae contained KF (1.38mg), magnesium stearate (1%w/w), Aerosil 200 (2%w/w),  mint    flavor 
(0.5%w/w) and aspartam (1%w/w). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formula 
No 
Disintegrant 
 
Binder 
 
Diluent 
 F1 
3%
 A
c-
di
-s
ol
 
10% Avicel PH-101 Mannitol 
F2 10% Avicel PH-101 Lactose 
F3 10% PEG 6000 Mannitol 
F4 10% PEG 6000 Lactose 
F5 
3%
 E
xp
lo
ta
b 
10% Avicel PH-101 Mannitol 
F6 10% Avicel PH-101 Lactose 
F7 10% PEG 6000 Mannitol 
F8 10% PEG 6000 Lactose 
F9 
5%
  A
c-
di
-s
ol
 
10% Avicel PH-101 Mannitol 
F10 10% Avicel PH-101 Lactose 
F11 10% PEG 6000 Mannitol 
F12 10% PEG 6000 Lactose 
F13 
5%
 E
xp
lo
ta
b 
10% Avicel PH-101 Mannitol 
F14 10% Avicel PH-101 Lactose 
F15 10% PEG 6000 Mannitol 
F16 10% PEG 6000 Lactose 
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Table 2. Randomization plan of two Ketotifen fumarate formulae F9 and Fc9 FDSLTs. The conventional  
product Zaditen® (1mg) tablets 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Evaluation data of the prepared KF Fast disintegrating sublingual tablets.  
 
 
Formula 
number 
Mean 
Diameter 
(cm) 
± S.D. 
Mean  
Thickness 
(cm) 
± S.D. 
% Drug 
Content  ± 
S.D. 
 
Hardness 
±S.D** 
(Kg) 
%  Loss in 
tablet weight 
(Friability) 
 
Average 
Disintegration 
Time ±S.D.* 
(Seconds) 
F1 0.705 (±0.012) 
0.209 
(±0.012) 105.62 ±0.81 6.8475±0.2085 0.768 64.52±4.435 
F2 0.708 (±0.014) 
0.205 
(±0.007) 93.61±1.472 6.319±0.104 0.829 66.17±3.11 
F3 0.714 (±0.002) 
0.206 
(±0.015) 112.71±2.01 7.175±1.023 0.753 61.15±6.20 
F4 0.709 (±0.000) 
0.200 
(±0.019) 96.25 ±0.932 7.6185±0.846 0.896 77.227±6.38 
F5 0.711 (±0.019) 
0.215 
(±0.008) 109.62±2.57 6.5815±0.632 0.947 72.49±6.59 
F6 0.702 (±0.007) 
0.216 
(±0.022) 101.55±0.98 6.766±0.462 0.663 84.558±4.12 
F7 0.727 (±0.003) 
0.209 
(±0.009) 97.364±1.49 6.825±0.316 0.825 87.95±5.28 
F8 0.720 (±0.014) 
0.209 
(±0.009) 102.55±3.11 7.225±0.881 0.654 100.20±6.615 
F9 0.712 (±0.011) 
0.213 
(±0.019) 94.317±3.81 4.14±0.1565 0.397 24.13±2.012 
F10 0.709 (±0.016) 
0.211 
(±0.016) 112.17 ±0.96 4.49±0.285 1.28 34.79±3.76 
F11 0.710 (±0.002) 
0.209 
(±0.035) 99.037±1.95 5.47±0.185 0.479 37.68 ±1.55 
F12 0.708 (±0.089) 
0.204 
(±0.004) 105.810±2.0 5.395±0.612 0.862 48.08±4.784 
F13 0.709 (±0.029) 
0.200 
(±0.000) 93.91 ±1.70 4.26±0.218 0.975 28.625±2.63 
F14 0.715 (±0.202) 
0.201 
(±0.003) 90.48 ±1.492 4.78±0.571 1.13 35.675±4.405 
F15 0.710 (±0.169) 
0.216 
(±0.013) 109.05±2.31 4.67±0.375 0.812 44.195±3.37 
F16 0.700 (±0.092) 
0.218 
(±0.018) 98.49±1.51 4.85±0.138 0.587 49.525±2.682 
 
Volunteer 
Number Phase I Phase II Phase III 
1 F9 Fc9 Zaditen 
2 Fc9 F9 Zaditen 
3 Zaditen F9 Fc9 
4 F9 Zaditen Fc9 
5 Fc9 Zaditen F9 
6 Zaditen Fc9 F9 
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Table 4. Characterization of ketotifen fumarate/ 2-HP-β-CD fast disintegrating sublingual tablet 
 
Formula 
Number 
 
% of drug 
content ±S.D. 
Hardness 
(Kg)±S.D. Friability 
In-vitro 
disintegration 
time(sec.)±S.D 
Disintegration 
Time in the 
Buccal 
Cavity   (sec.) 
 
% of KF 
after 1 
minute 
FC1 99.18±0.99 6.57±0.74 0.795 57.27±3.57 68.2±4.63 70.24 
FC2 101.58±1.37 6.31±0.42 0.903 1460.42±4. 43.11±3.02 66.34 
FC3 99.91±2.15 7.08±1.34 0.779 53.79±2.12 54.6±5.36 58.36 
FC9 98.18±2.65 4.452±0.72 0.405 421.26±2.7 21.19±2.89 80.26 
FC11 102.47±0.93 4.58±0.84 0.479 36.87±3.15 39.27±4.14 61.71 
FC12 99.33±1.97 5.32±0.31 0.748 39.79 ±6.21 70.48±8.50 78.39 
FC13 98.44±1.76 4.71±0.72 00.85 27.80±2.09 27.25±4.82 39.84 
FC16 102.57±3.80 4.08±0.55 0.611 40.15±4.36 46.37±5.43 70.24 
 
 
Table 5. pharmacokinetic parameters ±S.D of Ketotifen fumarate following the administration of a single 
oral dose (1.38 mg) of the market formula (Zaditen® tablets), the selected sublingual tablet formula (F9) 
and (Fc9). 
 
Pharmacokinetic parameter 
Formula 
 
(Zaditen® tablets)  
F9 
 
 
Fc9 
 Cpmax (ng/ml) 16.0857±1.628  
25.578±2.65 
 
 
30.901±4.963 
 tmax  (hr) 1.9167±0.204 1.167±0.258  
1.083±0.186 
 AUC(0-24) (ng.hr/ml) 161.237 ±16.78 210.102±36.99 246.192±32.33 
AUC(0-∞) (ng.hr/ml)   
264.940±22.475 
 
319.894± 69.137 382.166±55.278 
K  (hr-1) 0.038817 
±0.0094 
0.0434 
±0.0038 
0.0435 
±0.0055 
t ½ (hr) 18.567±3.615 16.086±1.487 16.234±2.211 
* t1/2: Elimination half-life.                                                **K: Elimination rate constant. 
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Figure 1. Chart plots for the mean effect of tablets hardness of different formulae from Ketotifen 
fumarate fast disintegrating sublingual tablets.  
    (a) Superdisintegrant type                   (b) Superdisintegrant concentration  
    (c) Diluent type                                    (d) Binder type 
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Figure 2: Chart plots for the mean effect of tablets disintegration time of different formulae From 
Ketotifen fumarate Fast disintegrating sublingual tablets. 
 (a) Superdisintegrant type               (b) Superdisintegrant concentration 
(c) Binder type                                 (d) Diluent type 
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 Figure (3):  DSC thermograms of KF/2-Hydroxyypropyl-β-cyclodextrin solid systems. 
(a) Pure Ketotifen fumarate; (b) Pure HP-β-CD (c) Physical mixture (d) Coprecipitation. 
 
 
Figure (4): X-ray diffraction patterns of KF/2-Hydroxypropyl-β-cyclodextrin solid systems. 
(a) Pure Ketotifen fumarate  (b) Pure HP-β-CD(c) Physical mixture (d) Coprecipitation 
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Figure 5: The average buccal disintegration time and the percent of KF after1 minute of the 
selected KF fast disintegrating sublingual tablets 
 
 
 
Figure 6:  Dissolution of ketotifen fumarate from the selected tablet formulae for choosing the 
best formula (n=3± S.D.). 
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Figure 7:  Dissolution of Ketotifen Fumarate from the selected Tablet Formulae for    
choosing the    best formula (n=3± S.D.)  
 
 
 
 
Figure 8:  Plasma concentration of ketotifen fumarate following the administration of treatments 
Zaditen® tablets, F9 tablets and Fc9 tablets.  Data represent the mean values of  n=6 ± S.D. 
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